Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer disease is a research paper published in medRxiv (2024). On theSindex it has a DataRank of 0. It has been cited 4 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 5R01AG065234-03
Returning Research Results that Indicate Risk of Alzheimer Disease to Healthy Participants in Longitudinal Studies
National Institutes of Health
Grant: 5P01AG003991-38
Healthy Aging and Senile Dementia
National Institutes of Health
Grant: 5R01AA029308-05
Investigating the longitudinal relationship between alcohol use, neurophysiological functioning, and Alzheimer disease biomarkers in the Collaborative Study on the Genetics of Alcoholism
National Institutes of Health
Grant: 1P30AG066444-01
Alzheimer's Disease Research Center
National Institutes of Health
Grant: 5R01AG067505-05
Cross Sectional and Longitudinal Racial Disparity in Molecular Biomarkers of Alzheimer Disease
National Institutes of Health
Grant: 5P01AG026276-07
Antecedent Neuroimaging Biomarkers
National Institutes of Health
Grant: 5R01AG070941-02
Staging Alzheimer disease with blood-based biomarkers
National Institutes of Health
Grant: 1UL1TR002345-01
Washington University Institute of Clinical and Translational Sciences
Fields of Study
Keywords
Sustainable Development Goals